Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2015).
Articles in this Volume were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence.
Articles are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Sci. Pharm. 2015, 83(2), 269-278; doi:10.3797/scipharm.1502-05 (registering DOI)
A Validated HPLC/MS Limit Test Method for a Potential Genotoxic Impurity in Cilostazol and its Quantification in the API and in the Commercially Available Drug Product
R&D Department, Dipharma Francis srl, Via Bissone 5, Baranzate (MI), Italy.
*
Author to whom correspondence should be addressed.
Received: 19 February 2015 / Accepted: 26 March 2015 / Published: 26 March 2015
Download PDF [317 KB, uploaded 7 September 2016]
Abstract
Cilostazol is a selective inhibitor of type 3 phosphodiesterase. 5-(3-Chloro-propyl)-1-cyclohexyl-1H-tetrazole, used as an intermediate in the synthesis of cilostazol, has a primary alkyl chloride group, a well-known alerting function for genotoxic activity. Upon request from a regulatory agency, a limit test in accordance with ICH Q2(R1) added with the accuracy of a recovery test of 5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole in cilostazol was developed and validated. The application of the method highlighted the need to optimize the purification process to ensure levels of this potential genotoxic impurity in the final active pharmaceutical ingredient below the established limit. Also, the analytical method was suitable to determine the amount of the impurity in samples of the commercially available drug product, which showed the levels to be above the established threshold of toxicological concern (TTC).Keywords:
Cilostazol; Potential genotoxic impurity; HPLC/MS; Limit test method; Validation
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
BRAY, L.; MONZANI, L.; BRUNOLDI, E.; ALLEGRINI, P. A Validated HPLC/MS Limit Test Method for a Potential Genotoxic Impurity in Cilostazol and its Quantification in the API and in the Commercially Available Drug Product. Sci. Pharm. 2015, 83, 269-278.
Article Metrics
Comments
[Return to top]
Sci. Pharm.
EISSN 2218-0532
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert